Durban International CRS

Location	16 Charles Strachan, Westridge Durban, 4091 South Africa
CRS Coordinator	Rosie Mngqibisa mngqibisa@ecarefoundation.com 27-31-2611093
CRS Leader	Umesh Lalloo umeshlalloo@gmail.com 27-31-2604669
Studies	A5243: Non-US Genomic Sampling A5354: Early ART in Acute HIV A5300B:Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Participants (PHOENIx) A5381: Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART A5332: REPRIEVE Trial A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV A5372: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study) A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B